The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 201–300 of 1,006
Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013)
Buckle, D. R., Erhardt, P., Ganellin, C. R., Kobayashi, T., Perun, T. J., Proudfoot, J., & Senn‐Bilfinger, J. (2013) · Pure and Applied Chemistry · doi:10.1351/pac-rec-12-11-23 · Cited by 152
Senthil, S. L., Chandrasekaran, R., Arjun, H. A., & Anantharaman, P. (2019) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.01.039 · Cited by 162
Johannes, J. W., Balazs, A., Barratt, D. G., Biśta, M., Chuba, M. D., Cosulich, S. C., Critchlow, S. E., Degorce, S. L., Fruscia, P. D., Edmondson, S. D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01012 · Cited by 154
Parrott, N. J., Lukacova, V., Fraczkiewicz, G., & Bolger, M. B. (2009) · The AAPS Journal · doi:10.1208/s12248-008-9079-7 · Cited by 155
“Like many molecules currently reaching development ( 54 ), Aprepitant is highly lipophilic and has very low aqueous solubility.”
BackgroundDrug Promiscuity in PDB: Protein Binding Site Similarity Is Key
Haupt, V. J., Daminelli, S., & Schroeder, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065894 · Cited by 147
“The study of BioPrint (AstraZeneca, 2,133 compounds and 200 targets) showed similar results regarding hydrophobicity but found no general correlation between molecular weight and promiscuity [22].”
ResultMcDaniel, K. F., Wang, L., Soltwedel, T., Fidanze, S. D., Hasvold, L. A., Liu, D., Mantei, R. A., Pratt, J. K., Sheppard, G. S., Bui, M. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00746 · Cited by 135
Molecular Property Design: Does Everyone Get It?
Leeson, P. D., & Young, R. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00157 · Cited by 143
Self-citationEdwards, M. P., & Price, D. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45023-x · Cited by 147
Obaid, R. J., Naeem, N., Mughal, E. U., Al‐Rooqi, M. M., Sadiq, A., Jassas, R. S., Moussa, Z., & Ahmed, S. A. (2022) · RSC Advances · doi:10.1039/d2ra03081k · Cited by 156
Data-driven medicinal chemistry in the era of big data
Lusher, S. J., McGuire, R., van Schaik, R. C., Nicholson, C. D., & de Vlieg, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.004 · Cited by 150
Romero, F. A., Murray, J. M., Lai, K. W., Tsui, V., Albrecht, B. K., An, L., Beresini, M. H., Boenig, G. D. L., Bronner, S. M., Chan, E. W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00796 · Cited by 146
Porey, S., Zhang, X., Bhowmick, S., Singh, V. K., Guin, S., Paton, R. S., & Maiti, D. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10646 · Cited by 146
Linclau, B., Wang, Z., Compain, G., Paumelle, V., Fontenelle, C. Q., Wells, N. J., & Weymouth‐Wilson, A. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201509460 · Cited by 144
Konze, K. D., Bos, P. H., Dahlgren, M. K., Leswing, K., Tubert‐Brohman, I., Bortolato, A., Robbason, B., Abel, R., & Bhat, S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00367 · Cited by 161
The First CNS-Active Carborane: A Novel P2X7 Receptor Antagonist with Antidepressant Activity
Wilkinson, S. M., Gunosewoyo, H., Barron, M. L., Boucher, A., McDonnell, M., Turner, P., Morrison, D. E., Bennett, M. R., McGregor, I. S., Rendina, L. M., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500054n · Cited by 141
The Essential Roles of Chemistry in High-Throughput Screening Triage
Dahlin, J. L., & Walters, M. A. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.60 · Cited by 161
2,3-Dihydroquinazolin-4(1 H )-one as a privileged scaffold in drug design
Badolato, M., Aiello, F., & Neamati, N. (2018) · RSC Advances · doi:10.1039/c8ra02827c · Cited by 144
The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance
Darpö, B. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00487.x · Cited by 145
Kell, D. B., Dobson, P. D., Bilsland, E., & Oliver, S. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.008 · Cited by 154
Contributions of Molecular Properties to Drug Promiscuity
Tarcsay, Á., & Keserű, G. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301514n · Cited by 153
Desai, B. K., Dixon, K., Farrant, E., Feng, Q., Gibson, K. R., van Hoorn, W. P., Mills, J. E. J., Morgan, T., Parry, D. M., Ramjee, M. K., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400099d · Cited by 150
On the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2012) · MedChemComm · doi:10.1039/c2md20242e · Cited by 143
Yang, Y., Engkvist, O., Llinàs, A., & Chen, H. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201548z · Cited by 149
Lipophilic Efficiency: The Most Important Efficiency Metric in Medicinal Chemistry
Freeman‐Cook, K. D., Hoffman, R. L., & Johnson, T. W. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.208 · Cited by 139
Validity of Ligand Efficiency Metrics
Murray, C. W., Erlanson, D. A., Hopkins, A. L., Keserű, G. M., Leeson, P. D., Rees, D. C., Reynolds, C. H., & Richmond, N. J. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500146d · Cited by 150
Self-citationBettini, E., Sava, A., Griffante, C., Carignani, C., Buson, A., Capelli, A. M., Negri, M., Andreetta, F., Senar, S., Guiral, L., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172544 · Cited by 142
“…coefficient (cLogP), obtained with the use of Daylight 4.81 software (Daylight Chemical Information Systems, Laguna Niguel, CA) was used to calculate LLE to maximize the minimally acceptable lipophilicity per unit of in vitro potency, according to Leeson and Springthorpe (2007): LLE pIC50 cLogP.”
MethodInfluentialSolid-Phase Synthesis of Biologically Active Benzoannelated Nitrogen Heterocycles: An Update
Gil, C., & Bräse, S. (2008) · Journal of Combinatorial Chemistry · doi:10.1021/cc800102t · Cited by 138
‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries
Dobson, P. D., Patel, Y., & Kell, D. B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.011 · Cited by 144
Coimbra, J. T. S., Feghali, R., Ribeiro, R. P., Ramos, M. J., & Fernandes, P. A. (2021) · RSC Advances · doi:10.1039/d0ra09995c · Cited by 155
Considering the impact drug-like properties have on the chance of success
Yusof, I., & Segall, M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.008 · Cited by 137
Recent progress in fragment-based lead discovery
Schulz, M. N., & Hubbard, R. E. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.04.009 · Cited by 159
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106774 · Cited by 156
Yuan, J., Venkatraman, S., Zheng, Y., McKeever, B. M., Dillard, L. W., & Singh, S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301659n · Cited by 135
Thermodynamics guided lead discovery and optimization
Ferenczy, G. G., & Keserű, G. M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.013 · Cited by 151
Shirure, V. S., & George, S. C. (2017) · Lab on a Chip · doi:10.1039/c6lc01401a · Cited by 135
Barraza, S. J., & Denmark, S. E. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b03187 · Cited by 141
Identification of Novel Adenosine A2A Receptor Antagonists by Virtual Screening
Langmead, C. J., Andrews, S. P., Congreve, M., Errey, J. C., Hurrell, E., Marshall, F. H., Mason, J. S., Richardson, C. M., Robertson, N. J., Zhukov, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201455y · Cited by 145
Characteristics of known drug space. Natural products, their derivatives and synthetic drugs
Bade, R., Chan, H., & Reynisson, J. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.018 · Cited by 134
Promiscuity and selectivity of bitter molecules and their receptors
Pizio, A. D., & Niv, M. Y. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.025 · Cited by 150
Impact of Payload Hydrophobicity on the Stability of Antibody–Drug Conjugates
Buecheler, J. W., Winzer, M., Tonillo, J., Weber, C., & Gieseler, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00177 · Cited by 128
Plowright, A. T., Johnstone, C., Kihlberg, J. O., Pettersson, J. A., Robb, G. R., & Thompson, R. A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.012 · Cited by 135
An αv‐RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities
Hatley, R. J. D., Macdonald, S. J. F., Slack, R. J., Le, J., Ludbrook, S. B., & Lukey, P. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707948 · Cited by 137
Accessing Polysubstituted Quinazolines via Nickel Catalyzed Acceptorless Dehydrogenative Coupling
Parua, S., Sikari, R., Sinha, S., Chakraborty, G., Mondal, R., & Paul, N. D. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.8b01479 · Cited by 132
Zhao, H., Yang, Y., Wang, S., Yang, X., Zhou, K., Xu, C., Zhang, X., Fan, J., Hou, D., Li, X., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1069 · Cited by 151
Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors
Kuhn, B., Tichý, M., Wang, L., Robinson, S. D., Martin, R. E., Kuglstatter, A., Benz, J., Giroud, M., Schirmeister, T., Abel, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01881 · Cited by 133
Ma, Z.-M., Song, T., Yuan, Y., & Yang, Y. (2019) · Chemical Science · doi:10.1039/c9sc04060a · Cited by 132
Clear castable polyurethane elastomer for fabrication of microfluidic devices
Domansky, K., Leslie, D. C., McKinney, J., Fraser, J. P., Sliz, J. D., Hamkins-Indik, T., Hamilton, G. A., Bahinski, A., & Ingber, D. E. (2013) · Lab on a Chip · doi:10.1039/c3lc50558h · Cited by 129
Fragment-Based Lead Discovery and Design
Joseph-McCarthy, D., Campbell, A. J., Kern, G., & Moustakas, D. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci400731w · Cited by 129
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 129
Lipophilicity and biomimetic properties measured by HPLC to support drug discovery
Valko, K. L. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.04.009 · Cited by 129
Emerging Building Blocks for Medicinal Chemistry: Recent Synthetic Advances
Grygorenko, O. O., Volochnyuk, D. M., & Vashchenko, B. V. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100857 · Cited by 133
Pettersson, M., Hou, X., Kühn, M., Wager, T. T., Kauffman, G. W., & Verhoest, P. R. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00027 · Cited by 140
Quality guidelines for oral drug candidates: dose, solubility and lipophilicity
Bayliss, M. K., Butler, J., Feldman, P. L., Green, D. V. S., Leeson, P. D., Palovich, M. R., & Taylor, A. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.007 · Cited by 134
Self-citationLigand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
“Since then, the concept of ligand efficiency has been extended to include several new matrices including binding efficiency index (affinity/molecular weight), percentage efficiency index (% inhibition/molecular weight), surfacebinding efficiency index (affinity/van der Waals polar surface area) [37-39], kinetic effici…”
BackgroundObaid, R. J., Mughal, E. U., Naeem, N., Al‐Rooqi, M. M., Sadiq, A., Jassas, R. S., Moussa, Z., & Ahmed, S. A. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.06.009 · Cited by 129
Cyclic peptide oral bioavailability: Lessons from the past
Wang, C. K. L., & Craik, D. J. (2016) · Biopolymers · doi:10.1002/bip.22878 · Cited by 129
Is there enough focus on lipophilicity in drug discovery?
Planey, S. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1691995 · Cited by 143
Li, D., Zhan, P., Clercq, E. D., & Liu, X. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm200990c · Cited by 127
Metal‐Free Photocatalysts for C−H Bond Oxygenation Reactions with Oxygen as the Oxidant
Zhang, Y., Schilling, W., & Das, S. (2019) · ChemSusChem · doi:10.1002/cssc.201900414 · Cited by 124
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Unnikrishnan, M. K., Uddin, M. S., Mathew, G. E., Pratap, R., Marathakam, A., & Mathew, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.018 · Cited by 123
Applications of Physiologically Based Absorption Models in Drug Discovery and Development
Parrott, N. J., & Lavé, T. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000155 · Cited by 129
Using a Fragment‐Based Approach To Target Protein–Protein Interactions
Scott, D. E., Ehebauer, M. T., Pukala, T. L., Marsh, M., Blundell, T. L., Venkitaraman, A. R., Abell, C., & Hyvönen, M. (2013) · ChemBioChem · doi:10.1002/cbic.201200521 · Cited by 135
Jabeen, I., Pleban, K., Rinner, U., Chiba, P., & Ecker, G. F. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201705f · Cited by 135
Spyrakis, F., & Cavasotto, C. N. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.08.002 · Cited by 134
Lipophilicity and biomimetic properties to support drug discovery
Tsopelas, F. N., Giaginis, C., & Tsantili‐Kakoulidou, A. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1344210 · Cited by 125
Law, R. P., Atkinson, S. J., Bamborough, P., Chung, C.-W., Demont, E. H., Gordon, L. J., Lindon, M., Prinjha, R. K., Watson, A. J. B., & Hirst, D. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01666 · Cited by 117
Kell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
Current advances in drug discovery for Chagas disease
Scarim, C. B., Jornada, D. H., Chelucci, R. C., de Almeida, L., dos Santos, J. L., & Chung, M. C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.040 · Cited by 123
Encinas, L., O’Keefe, H. P., Neu, M., Remuiñán, M. J., Patel, A., Guardia, A. C., Davie, C. P., Pérez-Macías, N., Yang, H., Convery, M. A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401326j · Cited by 119
Drug discovery in the next decade: innovation needed ASAP
Bennani, Y. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.004 · Cited by 132
Mignani, S. M., Rodrigues, J., Tomás, H., Jalal, R., Singh, P. P., Majoral, J., & Vishwakarma, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.010 · Cited by 133
Shultz, M. D., Cheung, A. K., Kirby, C. A., Firestone, B., Fan, J., Chen, C. H.-T., Chen, Z., Chin, D. N., DiPietro, L., Fazal, A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400807n · Cited by 126
Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
Xu, X., Meng, Y., Li, L., Xu, P., Wang, J.-B., Li, Z.-Y., & Bian, J.-L. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00961 · Cited by 107
Ligand binding at the protein–lipid interface: strategic considerations for drug design
Payandeh, J., & Volgraf, M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00240-2 · Cited by 127
Tian, S., Wang, J., Li, Y., Xu, X., & Hou, T. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300198d · Cited by 118
Chen, M., Hong, H., Fang, H., Kelly, R., Zhou, G., Borlak, J., & Tong, W. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft189 · Cited by 115
“Moreover, some descriptors define the molecular shape (D242) and size (D123), which may affect off-target activities of drug candidates and thereby contribute to risk for DILI (Leeson and Springthorpe, 2007).”
Amphiphile regulation of ion channel function by changes in the bilayer spring constant
Lundbæk, J. A., Koeppe, R. E., & Andersen, O. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007455107 · Cited by 116
Molekulare Erkennung in chemischen und biologischen Systemen
Persch, E., Dumele∞, O., & Diederich, F. (2015) · Angewandte Chemie · doi:10.1002/ange.201408487 · Cited by 117
Drug and Drug Candidate Building Block Analysis
Wang, J., & Hou, T. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900398f · Cited by 116
Rational Methods for the Selection of Diverse Screening Compounds
Huggins, D. J., Venkitaraman, A. R., & Spring, D. R. (2011) · ACS Chemical Biology · doi:10.1021/cb100420r · Cited by 118
“Analysis of trends in launched drugs has highlighted a significant increase in molecular weight in the last fifty years, but a negligible increase in logP values(46).”
BackgroundEvolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery
Macalino, S. J. Y., Basith, S., Clavio, N. A. B., Chang, H., Kang, S., & Choi, S. (2018) · Molecules · doi:10.3390/molecules23081963 · Cited by 125
Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., Guise, C. P., Smaill, J. B., Patterson, A. V., Lambin, P., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.01.005 · Cited by 111
Agoni, C., Olotu, F. A., Ramharack, P., & Soliman, M. E. S. (2020) · Journal of Molecular Modeling · doi:10.1007/s00894-020-04385-6 · Cited by 128
Kumari, N., KUMARI, R. R., Dua, A., Singh, M., Kumar, R., Singh, P., Duyar‐Ayerdi, S., Pradeep, S., Ojesina, A. I., & Kumar, R. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300688 · Cited by 127
Assessing the lipophilicity of fragments and early hits
Mortenson, P. N., & Murray, C. W. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9435-z · Cited by 112
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
Young, R. J., & Leeson, P. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00180 · Cited by 121
Self-citationGleeson, M. P., Bravi, G., Modi, S. P., & Lowe, D. M. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.002 · Cited by 111
4‐Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
Lucas, X., Wohlwend, D., Hügle, M. J., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., & Günther, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307652 · Cited by 120
Rai, M., Singh, A. V., Paudel, N., Kanase, A., Falletta, E., Kerkar, P., Heyda, J., Barghash, R. F., Singh, S. P., & Šoóš, M. (2023) · Current Research in Toxicology · doi:10.1016/j.crtox.2023.100118 · Cited by 117
Hajduk, P. J., Galloway, W. R. J. D., & Spring, D. R. (2011) · Nature · doi:10.1038/470042a · Cited by 111
Reis, J., Cagide, F., Chavarria, D., Silva, T., Fernandes, C., Gaspar, A., Uriarte, E., Remião, F., Alcaro, S., Ortuso, F., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00527 · Cited by 111
Safety and secondary pharmacology: Successes, threats, challenges and opportunities
Valentin, J., & Hammond, T. G. (2008) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2008.05.007 · Cited by 112
“…in silico models exist to determine the potency at the hERG channel enabling to screen millions of virtual compounds, thus streamlining chemistry to avoid synthesising compounds likely to be potent hERG blockers (Lesson & Springthorpe, 2007; Gavaghan, Arnby, Blomberg, Strandlund & Boyer, 2007; Fig.”
BackgroundThe nature of ligand efficiency
Kenny, P. W. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0330-2 · Cited by 122
Visible-Light-Mediated Aerobic Oxidation of N -Alkylpyridinium Salts under Organic Photocatalysis
Jin, Y., Ou, L., Yang, H., & Fu, H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b07883 · Cited by 109
Dakin, L. A., Block, M. H., Chen, H., Code, E. L., Dowling, J. E., Feng, X., Ferguson, A. D., Green, I., Hird, A. W., Howard, T. D., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.098 · Cited by 111
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury
Ortega‐Alonso, A., Stephens, C. M., Lucena, M. I., & Andrade, R. J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050714 · Cited by 140
“Analysis of large sets of compounds revealed that the lipophilic compounds are more likely to produce toxic events [59,60].”
BackgroundAn efficient, reusable copper-oxide/carbon-nanotube catalyst for N-arylation of imidazole
Gopiraman, M., Babu, S. G., Khatri, Z., Wei, K., Kim, Y. A., Endo, M., Karvembu, R., & Kim, I. S. (2013) · Carbon · doi:10.1016/j.carbon.2013.06.005 · Cited by 107
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Roskoski, R. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106362 · Cited by 113
Compound Aggregation in Drug Discovery: Implementing a Practical NMR Assay for Medicinal Chemists
LaPlante, S. R., Carson, R. J., Gillard, J. R., Aubry, N., Coulombe, R., Bordeleau, S., Bonneau, P. R., Little, M., O’Meara, J. A., & Beaulieu, P. L. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400535b · Cited by 106
Haydon, D. J., Bennett, J. M., Brown, D., Collins, I., Galbraith, G., Lancett, P., Macdonald, R., Stokes, N. R., Chauhan, P. K., Sutariya, J. K., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016366 · Cited by 106
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.